Related Experiment Videos

Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions

J C O'Shea¹, J E Tcheng

¹Duke Clinical Research Institute, Durham, North Carolina 27705, USA. oshea002@mc.duke.edu

Journal of Thrombosis and Thrombolysis

|December 21, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

GP IIb/IIIa blockade in elective percutaneous coronary intervention.

Current pharmaceutical design·2004

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Heart (British Cardiac Society)·2003

Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.

Developments in biologicals·2003

Eptifibatide in percutaneous coronary intervention. A review.

Minerva cardioangiologica·2002

Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT--(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II Trial.

The American journal of cardiology·2001

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

The American journal of cardiology·2001

See all related articles